Consolidated NAV at 30 June was US$95mln,up from US$93.6mln.
The transition of the business through the diversification of legacy assets and investing in new opportunities in Asia is well underway, said chairman, John Croft.
“Early in the period, we announced our first new investment since Harmony Capital was appointed, in DocDoc, which we believe to be Asia's leading patient empowerment company.”
DocDoc uses proprietary data and clinical informatics across a network of physicians and hospitals to support patients to find high-quality medical care.
Net losses for the half-year were US$1.44mln (Half year 2017: US$1.03mln) with a consolidated loss per share of US$1.77.
“There is an increasing number of future investment opportunities open to ADAM,” added Croft.